Copanlisib and Volasertib Overcome Ibrutinib-Venetoclax Resistance via Targeting Pi3k-Akt Signaling and G2/M Cell Cycle Transition in Mantle Cell Lymphoma

Hematological Oncology - United Kingdom
doi 10.1002/hon.86_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Venetoclax as a Single Agent and in Combination With PI3K-MTOR1/2 Kinase Inhibitors Against Ibrutinib Sensitive and Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Novel Targeted Strategies to Overcome Microenvironment-Dependent Resistance in Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma

Cancer Discovery
Oncology
2019English

Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor

International Journal of Basic & Clinical Pharmacology
2014English

Zerumbone Induces G2/M Cell Cycle Arrest and Apoptosis via Mitochondrial Pathway in Jurkat Cell Line

Natural Product Communications
PharmacologyComplementaryPlant ScienceAlternative MedicineMedicineDrug Discovery
2014English

YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in McF-7 Cells via ERα and PI3K/Akt Pathways

Journal of Cancer
Oncology
2015English

AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest

PLoS ONE
Multidisciplinary
2016English

MicroRNA-21 Promotes Glioma Cell Proliferation and Inhibits Senescence and Apoptosis by Targeting SPRY1 via the PTEN/PI3K/AKT Signaling Pathway

CNS Neuroscience and Therapeutics
PsychiatryMental HealthPhysiologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy